Category Archives: Cell Therapy

Flax Day 0 Stem cell Therapy
Stem Cell therapy on 20 yr old arthritic Rodeo horse both knees have dramatic bony changes and this was a little boys best mount. The parents were in hopes to provide the team with at least one more season before a forced retirement. The followup range of motion comparisons are also here for your viewing.From:WichitaEquineViews:7 0ratingsTime:00:00More inScience Technology

Read the original:
Flax Day 0 Stem cell Therapy - Video

The number of children diagnosed with ASD/Autism is on the rise. The good news is that thanks to the option of Autism treatment with stem cell therapy at World Stem Cells Clinic, parents are enjoying the substantial improvements they are seeing in their children with ASD/Autism.

Cancun, Mexico (PRWEB) December 24, 2012

Autism is a serious developmental problem appearing in early childhood. Before a child turns three-years-old, ASD/Autism can usually be detected. Symptoms seen and the severity of a childs Autism will vary. Autism affects the ability of a child to interact and communicate with others.

Sadly, there is not a cure for Autism, but intensive Autism treatment early on can make an enormous difference in the lives of children who have this disorder.

Children who have ASD/Autism have difficulty meeting some of the typical developmental milestones. These milestones include learning to use the washroom, as well as talking and interacting with others. Children with ASD also tend to perform repetitive body movements (stimming), which can make family outings a challenge.

Kell

The mother of a patient who received Stem Cells Treatment for Autism at the World Stem Cells Clinic details the numerous accomplishments that her son Kell continues to make following stem cell therapy.

Kells mother states that due to the stem cell therapy he received, a completely new environment exists inside Kells body. Kell is now focusing on objects and doing things that he has never done before.

Kell mastered drinking from a straw in just two days and then began drinking from a typical cup of his own accord. Kells mother states that she previously attempted to teach him this skill to no avail. She is ecstatic that he decided to complete this task on his own.

Before his stem cell therapy treatments, Kell would choose something in the store to stim with. Another common occurrence was Kell jumping around in a whirlwind of chaos. However, the most recent trip was different from those before it. Kell actually moved alongside the family while they shopped. Before his stem cell treatment, the family would drag him along and keep him from finding objects to stim with.

The rest is here:
The Lives of Kell and Other Children with ASD are Changing Due to The Stem Cell Treatment They Received at the World ...

PURTIER PRESENTATION
Please contact Mr.SAMSIUR SAUDJANA @ JAKARTA :+6281699062 Live cell therapy is a very effective stem cell therapy for improving health and even disease treatment other than for beauty and anti-aging.From:SAMSIUR SAUDJANAViews:1 0ratingsTime:09:00More inScience Technology

Excerpt from:
PURTIER PRESENTATION - Video

LEUVEN, BELGIUM and MADRID, SPAIN--(Marketwire - Dec 19, 2012) - TiGenix ( EURONEXT BRUSSELS : TIG ), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts with different dosing regimens, designed to assess safety, feasibility, tolerance, and optimal dosing. The study is being conducted at 23 centers. The Company believes that this clinical trial can set the stage not only for the further development of Cx611 in RA, but also in a wide range of other autoimmune disorders.

The interim results cover the first three months of the Phase IIa's six-month follow-up, and the data are still blinded. The primary endpoint of this study is safety, and the data collected so far support the good safety profile of all three doses of Cx611. Only two patients (4%) have suffered serious adverse events and only in one case (2%) it led to discontinuation of the treatment. All other side effects were mild and transient.

"We are delighted to report that the safety profile of Cx611 appears to be excellent," said Eduardo Bravo, CEO of TiGenix. "We have recruited patients who have failed at least two biologicals. If, in addition to this promising safety data, we can demonstrate a first indication of efficacy in this difficult to treat patient population, we will have a strong rationale to move forward with this product. We are looking forward to reporting the final results of the study at the end of April 2013."

About TiGenix

TiGenix NV ( EURONEXT BRUSSELS : TIG ) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit http://www.tigenix.com.

Forward-looking informationThis document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond TiGenix' control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in TiGenix' expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

View post:
TiGenix: Positive Interim Safety Results of Phase IIa Rheumatoid Arthritis Study With Allogeneic Adult Stem Cells ...

Stem Cell Therapy at Integra Medical Center IMC
New Project 64From:OmarGonzalezMDViews:0 0ratingsTime:06:12More inScience Technology

Read the rest here:
Stem Cell Therapy at Integra Medical Center IMC - Video

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--

BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a proprietary bioreactor for production of its NurOwn stem cell therapy candidate. The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, significantly increasing its production capabilities by using a single clean room for multiple patients, reducing costs and time. The project is supported by a grant awarded by the Canada-Israel Industrial Research and Development Foundation (CIIRDF).

Under the terms of the agreement, the companies will develop a commercially viable, safe, reliable, and cost-effective bioreactor for scale-up of BrainStorms NurOwn stem cell therapy, using Octanes Automated Cell & Tissue Engineering System (ACTES) technology. The CIIRDF funding award was approved for a period of three years.

Octane is the ideal partner for us, since they have a particular expertise in developing automated production processes for mesenchymal cell therapy technologies, commented Dr. Adrian Harel, BrainStorms CEO. We are anxious to move ahead with this project, in order to be in a position to provide NurOwn as quickly as possible, and to as many patients as possible, in the near future.

The opportunity to work with BrainStorm on scaling-up the NurOwn production process is a particularly meaningful one, given the urgency of its target population, said Dr. Tim Smith, Octanes CEO. We are confident that our combined knowledge base and commitment to the project will help advance their product significantly closer to clinical use.

BrainStorm is currently conducting a Phase I/II clinical trial in ALS patients at the Hadassah Medical Center in Jerusalem and is planning to expand its clinical development in the USA, pending FDA approval. Towards that goal, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the companys website at http://www.brainstorm-cell.com.

About Octane Biotech

Octane develops innovative bioreactor-based systems to meet the production challenges inherent in the progressive scale-up of manual cell culture protocols. The companys unique Automated Cell & Tissue Engineering System (ACTES) solution integrates state-of-the-art bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech Inc. is one of three affiliated companies within the Octane Medical Group. For more information, visit the companys website at http://www.octaneco.com.

Continue reading here:
BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process